Li, Dong https://orcid.org/0000-0002-2265-6727
Sheppard, Sarah E. https://orcid.org/0000-0003-3480-8123
March, Michael E.
Battig, Mark R.
Surrey, Lea F. https://orcid.org/0000-0002-6944-2232
Srinivasan, Abhay S. https://orcid.org/0000-0002-0180-4719
Matsuoka, Leticia S.
Tian, Lifeng
Wang, Fengxiang
Seiler, Christoph
Dayneka, Jill https://orcid.org/0000-0003-1175-2390
Borst, Alexandra J. https://orcid.org/0000-0002-7316-8643
Matos, Mary C.
Paulissen, Scott M. https://orcid.org/0000-0002-9258-2380
Krishnamurthy, Ganesh
Nriagu, Bede https://orcid.org/0000-0003-3006-4796
Sikder, Tamjeed
Casey, Melissa
Williams, Lydia https://orcid.org/0000-0001-9232-3656
Rangu, Sneha
O’Connor, Nora
Thomas, Alexandria
Pinto, Erin
Hou, Cuiping
Nguyen, Kenny
Pellegrino da Silva, Renata
Chehimi, Samar N.
Kao, Charlly
Biroc, Lauren
Britt, Allison D. https://orcid.org/0000-0001-6601-0453
Queenan, Maria
Reid, Janet R. https://orcid.org/0000-0001-6253-3708
Napoli, Joseph A.
Low, David M.
Vatsky, Seth
Treat, James
Smith, Christopher L.
Cahill, Anne Marie
Snyder, Kristen M.
Adams, Denise M.
Dori, Yoav https://orcid.org/0000-0003-0531-8723
Hakonarson, Hakon https://orcid.org/0000-0003-2814-7461
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Center for Advancing Translational Sciences (1R21TR003331)
U.S. Department of Health & Human Services | NIH | Eunice Kennedy Shriver National Institute of Child Health and Human Development (ZIA-HD009003-01)
Article History
Received: 29 September 2022
Accepted: 24 April 2023
First Online: 1 June 2023
Competing interests
: H.H. and CHOP are equity holders in Nobias Therapeutics, which is developing MEK inhibitor therapy for complex lymphatic anomalies. D.M.A. is a consultant for Novartis Pharmaceuticals and Nobias. K.M.S. is a consultant for Novartis Pharmaceuticals, which makes Vijoice (alpelisib), a selective PI3Ka inhibitor. The remaining authors declare no competing interests.